Clinical characteristics of 6 patients with t(6;14)(p21.1;q32.3)
| Patient . | Age/sex . | Diagnosis . | Cytogenetics . |
|---|---|---|---|
| 1 | 63/F | 1988: AIHA | |
| 1992: DLBCL | 46, XX, 2p−, 6p−, 6q+, 7q−, 9p+, 11q−, 12p+, 13q−,14q+, 20p− | ||
| 2 | 74/F | Leukemic, low-grade B-cell lymphoma, NOS. | 46,XX, t(6;14)(p21.1;q32.3), add(6)(q13), del(7)(q33∼34), add(10)(p14), t(14;19)(q32;q13) [4] |
| WBC = 42.5 × 109/L (87% lymphocytes). | 46, XX [21] | ||
| AIHA | |||
| 3* | 47/M | SLVL | 46,XY,t(6;14)(p21;q32.3)[11]/46,XY [9] |
| 4 | 68/F | SMZL with focal transformation present in intra-abdominal lymph nodes. | 47,XX,t(6;14)(p21;q32), +12, + add(12)(q22) [9] |
| 5 | 51/M | Parotid gland biopsy with background extranodal marginal zone B-cell lymphoma (MALT) and focal areas of transformation to DLBCL. | 48,add(X)(p22),Y, del(1)(q21q43), add(2)(p25), +3, del(5)(q13q31), −6, ?add(12)(q24.3), add(14)(q32), der(14)t(6;14)(p21.1;q32),+18,+mar [9]/47,add(X)(p22), Y, add(1)(q21), del(1)(q21q43), add(2)(p25), del(5)(q13q31), −6, del(9)(p13), der(14)t(1;14)(q21;q32), +18, +mar [4] |
| 6 | 42/F | Parotid gland biopsy with background extranodal marginal zone B-cell lymphoma (MALT) and focal areas of transformation to DLBCL. | 47,X,−X,add(6)(q15),der(14)?t(6;14)(p21.1;q32.3),add(15)(p11),i(18)(q10),add(22)(p11), +2mar [5]/46,X,−X, ?t(3;14)(p25;q32), der(10)t(10;11)(q26;q13), add(12)(p11), der(14)?t(6;14)(q32.3;p21.1), add (15)(p11), i(18)(q10), add(22)(p11), + 2mar[3] |
| Patient . | Age/sex . | Diagnosis . | Cytogenetics . |
|---|---|---|---|
| 1 | 63/F | 1988: AIHA | |
| 1992: DLBCL | 46, XX, 2p−, 6p−, 6q+, 7q−, 9p+, 11q−, 12p+, 13q−,14q+, 20p− | ||
| 2 | 74/F | Leukemic, low-grade B-cell lymphoma, NOS. | 46,XX, t(6;14)(p21.1;q32.3), add(6)(q13), del(7)(q33∼34), add(10)(p14), t(14;19)(q32;q13) [4] |
| WBC = 42.5 × 109/L (87% lymphocytes). | 46, XX [21] | ||
| AIHA | |||
| 3* | 47/M | SLVL | 46,XY,t(6;14)(p21;q32.3)[11]/46,XY [9] |
| 4 | 68/F | SMZL with focal transformation present in intra-abdominal lymph nodes. | 47,XX,t(6;14)(p21;q32), +12, + add(12)(q22) [9] |
| 5 | 51/M | Parotid gland biopsy with background extranodal marginal zone B-cell lymphoma (MALT) and focal areas of transformation to DLBCL. | 48,add(X)(p22),Y, del(1)(q21q43), add(2)(p25), +3, del(5)(q13q31), −6, ?add(12)(q24.3), add(14)(q32), der(14)t(6;14)(p21.1;q32),+18,+mar [9]/47,add(X)(p22), Y, add(1)(q21), del(1)(q21q43), add(2)(p25), del(5)(q13q31), −6, del(9)(p13), der(14)t(1;14)(q21;q32), +18, +mar [4] |
| 6 | 42/F | Parotid gland biopsy with background extranodal marginal zone B-cell lymphoma (MALT) and focal areas of transformation to DLBCL. | 47,X,−X,add(6)(q15),der(14)?t(6;14)(p21.1;q32.3),add(15)(p11),i(18)(q10),add(22)(p11), +2mar [5]/46,X,−X, ?t(3;14)(p25;q32), der(10)t(10;11)(q26;q13), add(12)(p11), der(14)?t(6;14)(q32.3;p21.1), add (15)(p11), i(18)(q10), add(22)(p11), + 2mar[3] |
AIHA indicates autoimmune hemolytic anemia; NOS, not otherwise specified; WBC, white blood cell count.
Patient was a 47-year-old asymptomatic man who was found to have a lymphocytosis, but neither lymphadenopathy nor hepatosplenomegaly, on routine testing. WBC was 30 × 109/L with 73% lymphocytes, whereas bone marrow aspirate contained 80% mature lymphoid cells. Morphology and immunophenotype from blood and marrow were consistent with SLVL, namely, positive staining with CD19, CD20, CD22, CD79a, strong sIgM/Dκ and weak FMC7. CD5 was positive in 39% of cells; CD10 and CD23 were both negative.